<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3067">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04813718</url>
  </required_header>
  <id_info>
    <org_study_id>PostCov</org_study_id>
    <nct_id>NCT04813718</nct_id>
  </id_info>
  <brief_title>Post COVID-19 Syndrome and the Gut-lung Axis</brief_title>
  <official_title>Post COVID-19 Syndrome: A Pilot Study to Explore the Gut-lung Axis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CBmed Ges.m.b.H.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The outbreak of the novel coronavirus (SARS-CoV-2)-infected disease (COVID-19) began in&#xD;
      December 2019, spread throughout China in early 2020 and developed as a pandemic thereafter.&#xD;
&#xD;
      Based on current knowledge, Covid-19 infection causes mild to moderate respiratory and&#xD;
      gastrointestinal symptoms in the majority of patients. In a smaller percentage severe disease&#xD;
      courses are observed, often with the need of hospitalization and intensive care treatment.&#xD;
      Apparently, symptoms can persist for relatively long time after viral clearance, suggesting&#xD;
      the existence of a &quot;Post-Covid&quot; syndrome. A study from the UK identified fatigue,&#xD;
      breathlessness and psychosocial stress as common symptoms after discharge from the hospital.&#xD;
      Covid-19 infection is frequently characterized by a hyperinflammatory phenotype and a&#xD;
      cytokine storm. The Covid-19 cytokine storm is characterised by rapid proliferation and&#xD;
      hyperactivation of T cells, macrophages, mast cells, neutrophil granulocytes and natural&#xD;
      killer cells, and the overproduction of inflammatory cytokines and chemical mediators&#xD;
      released by immune or nonimmune cells. Early data also suggest that even if symptoms are just&#xD;
      'mild to moderate' during the acute infection, fibrotic lung damage develops in some&#xD;
      patients. This may lead to long-term pulmonary complications for a subset of patients. The&#xD;
      mechanisms for post-Covid pulmonary fibrosis are still unclear: inflammation triggering&#xD;
      fibrosis, epithelial and endothelial injury with inadequate fibroproliferation and vascular&#xD;
      damage are considered to be possible mechanisms.&#xD;
&#xD;
      A potential therapeutic target in ameliorating post-Covid symptoms could be the gut&#xD;
      microbiome. Gut microbiome alterations have been described in Covid-19. The gut-lung axis as&#xD;
      a link between dysbiosis, barrier dysfunction, translocation of bacterial products and&#xD;
      hyperinflammation has been proposed as a potential therapeutic target. Probiotics have been&#xD;
      proposed to be a possible modulator of the deranged gut-lung axis in Covid-disease and&#xD;
      post-Covid syndrome. Currently 11 studies are registered in clinicaltrials.gov for treatment&#xD;
      of acute Covid disease and prevention of the disease (including one study from Graz), but no&#xD;
      study related to post-Covid syndrome could be found.&#xD;
&#xD;
      Therefore, it is currently unclear, which clinical, immune system or microbiome related&#xD;
      biomarker would be the best to study the effect of a microbiome-based intervention in&#xD;
      post-Covid syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiome composition</measure>
    <time_frame>6 months</time_frame>
    <description>16 sRNA sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intestinal barrier</measure>
    <time_frame>6 months</time_frame>
    <description>Change in zonulin levels over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sCD14</measure>
    <time_frame>6 months</time_frame>
    <description>Change in sCD14 levels over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>endotoxin</measure>
    <time_frame>6 months</time_frame>
    <description>Change in endotoxin levels serum over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TNFalpha</measure>
    <time_frame>6 months</time_frame>
    <description>Change in TNFalpha levels serum over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin 1b</measure>
    <time_frame>6 months</time_frame>
    <description>Change in Interleukin 1b serum levels over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin 6</measure>
    <time_frame>6 months</time_frame>
    <description>Change in interleukin 6 serum levels over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin 6 receptor</measure>
    <time_frame>6 months</time_frame>
    <description>Change in Interleukin 6 receptor serum levels over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>interleukin 8</measure>
    <time_frame>6 months</time_frame>
    <description>Change in interleukin 8 serum levels over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>interleukin 10</measure>
    <time_frame>6 months</time_frame>
    <description>Change in interleukin 10 serum levels over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>interleukin 17</measure>
    <time_frame>6 months</time_frame>
    <description>Change in interleukin 17 serum levels over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>interleukin 23</measure>
    <time_frame>6 months</time_frame>
    <description>Change in interleukin 23 serum levels over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neutrophil function burst function</measure>
    <time_frame>6 months</time_frame>
    <description>Change in neutrophil burst function over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neutrophil function phagocytosis</measure>
    <time_frame>6 months</time_frame>
    <description>Change in neutrophil phagocytosis function over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neutrophil NET formation</measure>
    <time_frame>6 months</time_frame>
    <description>Change in neutrophil NET formation over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neutrophil surface receptor expression</measure>
    <time_frame>6 months</time_frame>
    <description>Change in neutrophil surface receptor expression over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>monocyte burst</measure>
    <time_frame>6 months</time_frame>
    <description>Change in monocyte burst over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>monocyte phagocytosis</measure>
    <time_frame>6 months</time_frame>
    <description>Change in monocyte phagocytosis over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>monocyte function surface receptor expression</measure>
    <time_frame>6 months</time_frame>
    <description>Change in monocyte surface receptor expression over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T cell immunophenotyping</measure>
    <time_frame>6 months</time_frame>
    <description>Change in T cell subtypes over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B cells immunophenotyping</measure>
    <time_frame>6 months</time_frame>
    <description>Change in B cell subtypes over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry</measure>
    <time_frame>6 months</time_frame>
    <description>Change in spirometry measurements over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung volume</measure>
    <time_frame>6 months</time_frame>
    <description>Change in lung volume over time and with/without the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gas diffusion</measure>
    <time_frame>6 months</time_frame>
    <description>Change in pulmonary gas diffusion over time and with/without the intervention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Synbiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omni-Biotic Pro Vi 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>similar looking and tasting</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omni-Biotic Pro Vi 5</intervention_name>
    <description>Pre- and probiotic</description>
    <arm_group_label>Synbiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Covid-19 infection with severe disease defined within the last 12 months (defined as&#xD;
             one or more of the following: hospitalization, need for oxygen supply, need for&#xD;
             intensive care treatment, need for specific treatment of Covid disease, antibiotic&#xD;
             treatment)&#xD;
&#xD;
          -  Subjective presence of residual symptoms of Covid disease OR no residual symptoms of&#xD;
             Covid disease (Controls)&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Continuous probiotic treatment in the last 4 weeks before inclusion&#xD;
&#xD;
          -  Pre-existing lung diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be shared upon reasonable request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

